Skip to main content

Table 1 Baseline demographic and clinical characteristics of the study population

From: The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage

Variables Group A Group B Group C P- value
Numbers 16 16 16 -
Age, y 53.1 ± 6.3 46.9 ± 11.7 49.8 ± 10.1 0.288*
Sex, male/female 8/8 9/7 10/6 0.776†
Hypertension (%) 43.75% 50% 31.25% 0.549†
Vitreous hemorrhage grading scale     0.557†
2 3 2 2  
3 4 3 2  
4 9 11 12  
  1. * Kruskal–Wallis H test. † χ2 test